Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation
Atrial Fibrillation (AF) is associated with significant increase of stroke and other ischemic events risk. Anticoagulation to prevent ischemic strokes is a critical component of this condition management. Direct oral anticoagulants (DOACs)—with more predictable pharmacokinetics, ease of use and favo...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
InterMedservice
2022-03-01
|
| Series: | Евразийский Кардиологический Журнал |
| Online Access: | https://www.heartj.asia/jour/article/view/6308 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849245011341737984 |
|---|---|
| author | article Editorial |
| author_facet | article Editorial |
| author_sort | article Editorial |
| collection | DOAJ |
| description | Atrial Fibrillation (AF) is associated with significant increase of stroke and other ischemic events risk. Anticoagulation to prevent ischemic strokes is a critical component of this condition management. Direct oral anticoagulants (DOACs)—with more predictable pharmacokinetics, ease of use and favorable safety and efficacy profile—are the preferred anticoagulants for patients with atrial fibrillation. This retrospective study compares major ischemic and hemorrhagic outcomes in big cohort of patients 65+ y.o. with atrial fibrillation treated with rivaroxaban or apixaban (Ray, W. A. et al., 2021). |
| format | Article |
| id | doaj-art-7a0ad3ba5a244eadaa4bc3a2263038b7 |
| institution | Kabale University |
| issn | 2225-1685 2305-0748 |
| language | Russian |
| publishDate | 2022-03-01 |
| publisher | InterMedservice |
| record_format | Article |
| series | Евразийский Кардиологический Журнал |
| spelling | doaj-art-7a0ad3ba5a244eadaa4bc3a2263038b72025-08-20T03:58:59ZrusInterMedserviceЕвразийский Кардиологический Журнал2225-16852305-07482022-03-01011001016260Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillationarticle EditorialAtrial Fibrillation (AF) is associated with significant increase of stroke and other ischemic events risk. Anticoagulation to prevent ischemic strokes is a critical component of this condition management. Direct oral anticoagulants (DOACs)—with more predictable pharmacokinetics, ease of use and favorable safety and efficacy profile—are the preferred anticoagulants for patients with atrial fibrillation. This retrospective study compares major ischemic and hemorrhagic outcomes in big cohort of patients 65+ y.o. with atrial fibrillation treated with rivaroxaban or apixaban (Ray, W. A. et al., 2021).https://www.heartj.asia/jour/article/view/6308 |
| spellingShingle | article Editorial Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation Евразийский Кардиологический Журнал |
| title | Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation |
| title_full | Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation |
| title_fullStr | Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation |
| title_full_unstemmed | Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation |
| title_short | Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation |
| title_sort | association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation |
| url | https://www.heartj.asia/jour/article/view/6308 |
| work_keys_str_mv | AT articleeditorial associationofrivaroxabanvsapixabanwithmajorischemicorhemorrhagiceventsinpatientswithatrialfibrillation |